- A Case of Advanced Hepatocellular Carcinoma with Long-term Post-progression Survival under Repeated Transarterial Chemoembolization after Sorafenib Failure
-
Jihyun Lee, Hwi Young Kim, Yong Jin Jung, Tae Hun Kim, Kwon Yu
-
J Liver Cancer. 2017;17(1):82-87. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.82
-
-
 Abstract
 PDF
- Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide.
Only 30% of patients are eligible for curative surgical resection at diagnosis. For patients with
advanced hepatocellular carcinoma with accompanying portal vein tumor thrombosis, Sorafenib
is recommended as first-line treatment. However, survival gain from sorafenib is unsatisfactory,
and there is no standard therapy for patients who are intolerable or refractory to sorafenib. Here
we report a case of a 52-year-old man who initially achieved partial response after sorafenib
treatment, but eventually showed disease progression and was treated subsequently with
transarterial chemoembolization (TACE). Multinodular recurrence occurred, but he was treated
with repeated TACE, and has survived for 4 years so far.
|
E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Follow JLC on Twitter